Shares of Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA – Get Rating) have received an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $18.14.
A number of research firms have recently commented on AYLA. Raymond James cut their target price on Ayala Pharmaceuticals from $24.00 to $6.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 30th. Maxim Group dropped their price objective on Ayala Pharmaceuticals from $22.00 to $12.00 in a research note on Wednesday, March 30th. Finally, Oppenheimer dropped their price objective on Ayala Pharmaceuticals from $25.00 to $16.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 30th.
A number of institutional investors have recently bought and sold shares of AYLA. Wellington Management Group LLP lifted its holdings in Ayala Pharmaceuticals by 36.5% during the third quarter. Wellington Management Group LLP now owns 961,609 shares of the company’s stock worth $10,905,000 after buying an additional 257,246 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Ayala Pharmaceuticals by 406,248.7% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,153,648 shares of the company’s stock valued at $18,328,000 after purchasing an additional 2,153,118 shares during the last quarter. CSS LLC IL purchased a new stake in shares of Ayala Pharmaceuticals during the 4th quarter valued at $131,000. Finally, DLD Asset Management LP purchased a new stake in shares of Ayala Pharmaceuticals during the 4th quarter valued at $1,347,000. Institutional investors own 56.07% of the company’s stock.
Ayala Pharmaceuticals (NASDAQ:AYLA – Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.05. The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $0.88 million. Ayala Pharmaceuticals had a negative return on equity of 115.40% and a negative net margin of 1,403.90%. As a group, analysts predict that Ayala Pharmaceuticals will post -2.55 EPS for the current fiscal year.
Ayala Pharmaceuticals Company Profile (Get Rating)
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (AYLA)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.